163 related articles for article (PubMed ID: 34654743)
1. Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents.
Wei H; Wiśniowska A; Fan J; Harvey P; Li Y; Wu V; Hansen EC; Zhang J; Kaul MG; Frey AM; Adam G; Frenkel AI; Bawendi MG; Jasanoff A
Proc Natl Acad Sci U S A; 2021 Oct; 118(42):. PubMed ID: 34654743
[TBL] [Abstract][Full Text] [Related]
2. Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via
Zhang J; Ning Y; Zhu H; Rotile NJ; Wei H; Diyabalanage H; Hansen EC; Zhou IY; Barrett SC; Sojoodi M; Tanabe KK; Humblet V; Jasanoff A; Caravan P; Bawendi MG
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2220036120. PubMed ID: 37094132
[TBL] [Abstract][Full Text] [Related]
3. Size and PEG Length-Controlled PEGylated Monocrystalline Superparamagnetic Iron Oxide Nanocomposite for MRI Contrast Agent.
Deng LH; Jiang H; Lu FL; Wang HW; Pu Y; Wu CQ; Tang HJ; Xu Y; Chen TW; Zhu J; Shen CY; Zhang XM
Int J Nanomedicine; 2021; 16():201-211. PubMed ID: 33447035
[TBL] [Abstract][Full Text] [Related]
4. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.
Evans RJ; Lavin B; Phinikaridou A; Chooi KY; Mohri Z; Wong E; Boyle JJ; Krams R; Botnar R; Long NJ
Nanotheranostics; 2020; 4(4):184-194. PubMed ID: 32637296
[No Abstract] [Full Text] [Related]
5. EDTMP ligand-enhanced water interactions endowing iron oxide nanoparticles with dual-modal MRI contrast ability.
Hao L; Wang P; Wu Z; Wang Z; Wang Y; Zhu Y; Xu Z; Guo M; Ji J; Zhang P
J Mater Chem B; 2021 Nov; 9(43):9055-9066. PubMed ID: 34673872
[TBL] [Abstract][Full Text] [Related]
6. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents.
Wei H; Bruns OT; Kaul MG; Hansen EC; Barch M; Wiśniowska A; Chen O; Chen Y; Li N; Okada S; Cordero JM; Heine M; Farrar CT; Montana DM; Adam G; Ittrich H; Jasanoff A; Nielsen P; Bawendi MG
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2325-2330. PubMed ID: 28193901
[TBL] [Abstract][Full Text] [Related]
7. Investigation of blood-brain barrier permeability to magnetite-dextran nanoparticles (MD3) after osmotic disruption in rats.
Rousseau V; Denizot B; Pouliquen D; Jallet P; Le Jeune JJ
MAGMA; 1997 Sep; 5(3):213-22. PubMed ID: 9351025
[TBL] [Abstract][Full Text] [Related]
8. Redox-triggered aggregation of ESIONPs with switchable
He Y; Cao Y; Mao Z; Zhou Y; Zhang Y; Pei R
J Mater Chem B; 2021 Feb; 9(7):1821-1832. PubMed ID: 33508067
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting and excretable ultrasmall SPIONs for T
Du C; Liu X; Hu H; Li H; Yu L; Geng D; Chen Y; Zhang J
J Mater Chem B; 2020 Mar; 8(11):2296-2306. PubMed ID: 32100784
[TBL] [Abstract][Full Text] [Related]
10. Impact of surface coating and particle size on the uptake of small and ultrasmall superparamagnetic iron oxide nanoparticles by macrophages.
Saito S; Tsugeno M; Koto D; Mori Y; Yoshioka Y; Nohara S; Murase K
Int J Nanomedicine; 2012; 7():5415-21. PubMed ID: 23091384
[TBL] [Abstract][Full Text] [Related]
11. Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging.
Unterweger H; Janko C; Schwarz M; Dézsi L; Urbanics R; Matuszak J; Őrfi E; Fülöp T; Bäuerle T; Szebeni J; Journé C; Boccaccini AR; Alexiou C; Lyer S; Cicha I
Int J Nanomedicine; 2017; 12():5223-5238. PubMed ID: 28769560
[TBL] [Abstract][Full Text] [Related]
12. New strategies to prolong the in vivo life span of iron-based contrast agents for MRI.
Antonelli A; Sfara C; Battistelli S; Canonico B; Arcangeletti M; Manuali E; Salamida S; Papa S; Magnani M
PLoS One; 2013; 8(10):e78542. PubMed ID: 24223101
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility-based MRI contrast of the CSF by intravascular superparamagnetic nanoparticles.
Yu O; Namer IJ; Steibel J; Eclancher B; Poulet P; Chambron J
MAGMA; 1995; 3(3-4):169-72. PubMed ID: 8749736
[TBL] [Abstract][Full Text] [Related]
14.
Xu S; Wang J; Wei Y; Zhao H; Tao T; Wang H; Wang Z; Du J; Wang H; Qian J; Ma K; Wang J
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56701-56711. PubMed ID: 33296181
[TBL] [Abstract][Full Text] [Related]
15. Ultrasmall cationic superparamagnetic iron oxide nanoparticles as nontoxic and efficient MRI contrast agent and magnetic-targeting tool.
Uchiyama MK; Toma SH; Rodrigues SF; Shimada AL; Loiola RA; Cervantes Rodríguez HJ; Oliveira PV; Luz MS; Rabbani SR; Toma HE; Poliselli Farsky SH; Araki K
Int J Nanomedicine; 2015; 10():4731-46. PubMed ID: 26251595
[TBL] [Abstract][Full Text] [Related]
16. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging.
Stoll G; Bendszus M
Neuroscience; 2009 Feb; 158(3):1151-60. PubMed ID: 18651996
[TBL] [Abstract][Full Text] [Related]
17. Cerebral blood volume MRI with intravascular superparamagnetic iron oxide nanoparticles.
Kim SG; Harel N; Jin T; Kim T; Lee P; Zhao F
NMR Biomed; 2013 Aug; 26(8):949-62. PubMed ID: 23208650
[TBL] [Abstract][Full Text] [Related]
18. In vitro MRI of biodegradable hybrid (iron oxide/polycaprolactone) magnetic nanoparticles prepared via modified double emulsion evaporation mechanism.
Ahmed N; Ahmad NM; Fessi H; Elaissari A
Colloids Surf B Biointerfaces; 2015 Jun; 130():264-71. PubMed ID: 25960142
[TBL] [Abstract][Full Text] [Related]
19. Neuron labeling with rhodamine-conjugated Gd-based MRI contrast agents delivered to the brain via focused ultrasound.
Morse SV; Boltersdorf T; Harriss BI; Chan TG; Baxan N; Jung HS; Pouliopoulos AN; Choi JJ; Long NJ
Theranostics; 2020; 10(6):2659-2674. PubMed ID: 32194827
[TBL] [Abstract][Full Text] [Related]
20. Increased transverse relaxivity in ultrasmall superparamagnetic iron oxide nanoparticles used as MRI contrast agent for biomedical imaging.
Mishra SK; Kumar BS; Khushu S; Tripathi RP; Gangenahalli G
Contrast Media Mol Imaging; 2016 Sep; 11(5):350-361. PubMed ID: 27230705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
